TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01014767
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cycles 1 \& 2: 70 mg/m²/d IV over 6 hours on day 4
Study: NCT01014767
Drug: Dactinomycin
Normalized name: Dactinomycin
DrugBank: Dactinomycin (DB00970)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cycles 1 \& 2: 45 µg/kg/day (max. 2 mg), IV on day 1
Study: NCT01014767
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard Arm (1), Cycles 1 \& 2:~100 mg/m2 IV over 1 hour on days 1-5~All Arms, Cycles 4-6:~100 mg/m2 IV over 1 hour on days 1-5
Study: NCT01014767
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide Irinotecan arm (4), Cycles 1 \& 2:~50 mg/m2/day x 5 days as 1 hour IV infusions
Study: NCT01014767
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 150 mg/m2/day x 5 days orally and combined with irinotecan 50 mg/m2/day IV x 5 days as one hour infusions.
Study: NCT01014767
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard Arm (1), Cycles 1 \& 2 : 1.5 mg/m\^2 IV over 15 minutes on day 5~Doxorubicin/cisplatin arm (2), Cycles 1 \& 2: 1.5 mg/m\^2/day (max. 2 mg), i.v. on days 8, 15~For all Groups, Cycles 3 - 6: 1.5 mg/m2 IV over 15 minutes on day 5
Study: NCT02142335
Drug: Rituxan
Normalized name: Rituxan
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The dose of Rituxan is 375 mg/m2¬ administered as an IV infusion during weeks 1 \& 3 (days 1 \& 15)Abraxane will be administered at a fixed dose of 100 mg/m2 as an IV infusion weekly for three weeks in a row followed by one week of rest
Study: NCT01997593
Drug: intraperitoneal infiltration of ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intraperitoneal infiltration of ropivacaine by a special equipment
Study: NCT04551963
Drug: Zanubrutinib
Normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Capsules administered at a dose and frequency as specified in the treatment arm
Study: NCT04551963
Drug: Fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsules administered at a dose and frequency as specified in the treatment arm
Study: NCT04551963
Drug: Diltiazem
Normalized name: Diltiazem
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsules administered at a dose and frequency as specified in the treatment arm
Study: NCT04551963
Drug: Voriconazole
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsules administered at a dose and frequency as specified in the treatment arm
Study: NCT00033566
Drug: S-3304
Normalized name: S-3304
DrugBank: S-3304 (DB12149)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03332173
Drug: Zanubrutinib
Normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral administration using 80 mg capsules
Study: NCT02227030
Drug: BIIB 722 CL solution
Normalized name: CHLORIDE
DrugBank: Chloride ion (DB14547)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02227030
Drug: BIIB 722 CL tablet
Normalized name: CHLORIDE
DrugBank: Chloride ion (DB14547)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03425812
Drug: To continue NSAIDs therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NSAIDs therapy will be continued.
Study: NCT02520011
Drug: Alvocidib
Normalized name: Alvocidib
DrugBank: Alvocidib (DB03496)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02520011
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02520011
Drug: Mitoxantrone
Normalized name: Mitoxantrone
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00579969
Drug: Latanoprost
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: dosage form:eye drops, dosage: One drop in each eye twice a day
Study: NCT00579969
Drug: Timolol
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dosage form:eye drops, dosage: One drop in each eye twice a day
Study: NCT01866410
Drug: Cabozantinib S-malate
Normalized name: Cabozantinib S-Malate
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT01866410
Drug: Erlotinib Hydrochloride
Normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01995526
Drug: Insulin Peglispro
Normalized name: Insulin peglispro
DrugBank: Insulin peglispro (DB11567)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01229046
Drug: Ticarcillin-clavulanic acid
DrugBank: Clavulanic acid (DB00766)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 doses of IV ticarcillin-clavulanate infants \< 14 days PNA will receive 75 mg/kg Q12 infants ≥ 14 days PNA will receive 75 mg/kg Q8
Study: NCT02890745
Drug: Empagliflozin
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00910910
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: For patients with normal renal function (defined as CrCl ≥ 60 mL/min), 5 mg once daily on Days 1 through 28 of the first 28-day cycle, 10 mg once daily on Days 1 through 28 starting at the second cycle, 15 mg once daily starting at the third cycle and for the remainder of the study until PD or unacceptable toxicity, whichever occurs first.~For patients with moderate renal impairment (defined as CrCl ≥ 30 to \< 60 mL/min), 2.5 mg once daily on Days 1 through 28 of the first 28-day cycle, 5 mg once daily on Days 1 through 28 starting at the second cycle, 7.5 mg once daily starting at the third cycle and for the remainder of the study until PD or unacceptable toxicity, whichever occurs first.
Study: NCT00910910
Drug: Chlorambucil
Normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients assigned to the chlorambucil arm will receive oral chlorambucil tablets at 0.8 mg/kg on Days 1 and 15 of each 28-day cycle for a total duration of 12 months (approximately 13 cycles).
Study: NCT00135330
Drug: exenatide
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: subcutaneous injection, 5mcg or 10mcg, twice a day
Study: NCT00135330
Drug: rosiglitazone
Normalized name: Rosiglitazone
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral tablet, 2mg or 4mg, twice a day
Study: NCT01132846
Drug: Nesiritide
Normalized name: nesiritide
DrugBank: Nesiritide (DB04899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active Comparator: Low Dose Nesiritide~Participants randomized to the low dose nesiritide arm will receive nesiritide of 0.005 ug/kg/min or placebo during the first 72 hours in the trial.
Study: NCT04471376
Drug: Sugammadex
Normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sugammadex group received a rocuronium infusion producing blockade by qualitative train-of-four ≥2 at the ulnar nerve. 2 mg/kg of Sugammadex will be infused when conducting TcMEP
Study: NCT00931021
Drug: Varenicline (Chantix)
Normalized name: varenicline Oral Tablet [Chantix]
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 mg
Study: NCT00931021
Drug: Nicotine Patch
Normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 21 mg
Study: NCT02219932
Drug: fampridine
Normalized name: FAMPRIDINE
DrugBank: Dalfampridine (DB06637)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02506335
Drug: Cholate testing
Normalized name: cholate
DrugBank: Berberine ursodeoxycholate (DB18111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient receives simultaneously an oral dose of d4-cholate and an IV dose of 13C-cholate, which are stable isotopes; there is no radioactivity or radiation exposure.
Study: NCT04098653
Drug: Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine was administered at 20mg/m2/day on days -14 and -10.
Study: NCT04098653
Drug: Busulfan (BU)
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
Study: NCT02010593
Drug: Dapivirine Vaginal Ring
Normalized name: dapivirine
DrugBank: Dapivirine (DB08639)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapivirine, a non-nucleoside reverse-transcriptase inhibitor (NNRTI), is a substituted amino- pyrimidine (DAPY) derivative with potent antiviral activity against HIV-1. Dapivirine is chemically described as 4-\[\[4-\[(2,4,6-trimethylphenyl)amino\]-2- pyrimidinyl\]amino\]benzonitrile.6 The dapivirine matrix VR is a flexible ring containing 25 mg of drug substance dispersed in a platinum-catalyzed-cured silicone matrix. Dapivirine is known to be well-suited for delivery via VR
Study: NCT01703052
Drug: CHF 6001 SD or placebo
Normalized name: CHF-6001
DrugBank: CHF-6001 (DB12800)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry Powder Inhaler
Study: NCT01703052
Drug: CHF 6001 MD or placebo
Normalized name: CHF-6001
DrugBank: CHF-6001 (DB12800)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry Powder Inhaler
Study: NCT04359862
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 patients sedated with Sevoflurane via inhalation, starting with 6 ml/h and changing every 15 minutes until an adequate level of sedation is achieved ( BIS 40-50)
Study: NCT04359862
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 patients standard sedation with intravenous propofol, starting with 2 mg/kg/h and changing every 15 minutes until an adequate level of sedation is achieved ( BIS 40-50)
Study: NCT03688334
Drug: Oxygen 40 %
Normalized name: oxygen 40 %
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxygen supplementation (40%) via Venturi mask
Study: NCT03688334
Drug: Medical air (sham O2)
Normalized name: medical air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical air supplementation via Venturi mask
Study: NCT02374281
Drug: Water sucking
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01098448
Drug: systemic metronidazole and amoxicillin
Normalized name: metronidazole and diloxanide
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: systemic metronidazole (250 mg tid x 14) and amoxicillin (500 mg bid x 14
Study: NCT00253513
Drug: fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/m2, IV for 5 days
Study: NCT00253513
Drug: treosulfan
Normalized name: TREOSULFAN
DrugBank: Treosulfan (DB11678)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: 12 or 14 g/m2, IV for 5 days
Study: NCT03277001
Drug: Rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban, po. 10mg/day（CrCl≥ 50 ml/min）or 5 mg /day (CrCl ≥ 30 and \< 50 ml/min) po.
Study: NCT03277001
Drug: Enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 40mg IH
Study: NCT03442621
Drug: Relacorilant Fasted
Normalized name: Fast Freeze
DrugBank: Relacorilant (DB14976)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relacorilant, presented as 7 x 50-mg white, hard gelatin capsules for oral administration, given following a 10.5 h fast
Study: NCT00988052
Drug: Laquinimod
Normalized name: laquinimod
DrugBank: Laquinimod (DB06685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One capsule containing 0.6 mg laquinimod to be administered orally once daily.
Study: NCT02223052
Drug: CC-486
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm 1: Two 150-mg tablets of CC-486 on Day 1 and 1 x 300 mg CC-486 on Day 2 Arm 2: 1 x 300mg tablet of CC 486 on Day 1 and 2 x 150mg CC-486 on Day 2
Study: NCT02223052
Drug: Vidaza
Normalized name: Vidaza
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 75mg/m\^2 IV or SC daily x 7 days every 4 weeks for ≤ 6 (four-week) cycles
Study: NCT00849355
Drug: RCOMP-14 + rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pretreatment: vincristine 1mg at day -6 and Methylprednisolone 100 mg from -6 to day 0.~Treatment: rituximab 375m/m2 + ciclophosphamide 750 mg/m2 + Vincristine 1.4 mg/m2 + Doxorrubicine 50 mg/m2 at day 1 and every 14d. Prednisone 100 mg/d from day 1 to 5 and every 14 d.
Study: NCT03442621
Drug: Relacorilant with a high fat breakfast
Normalized name: Hard fat
DrugBank: Relacorilant (DB14976)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relacorilant presented as 7 x 50-mg white, hard gelatin capsules for oral administration, given following a 10 h fast and 0.5 h after the start of a high fat breakfast
Study: NCT03442621
Drug: Relacorilant with a moderate breakfast
Normalized name: Primatene with ephedrine Pill
DrugBank: Relacorilant (DB14976)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relacorilant, presented as 7 x 50-mg white, hard gelatin capsules for oral administration, given following a 10 h fast and 0.5 h after the start of a moderate breakfast
Study: NCT04428788
Drug: CC-94676
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT00394329
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate HFA (QVAR® 40 mcg Inhalation Aerosol) one puff bid
Study: NCT00394329
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate HFA (QVAR® 40 mcg Inhalation Aerosol) rescue puffs as needed
Study: NCT00394329
Drug: Albuterol sulfate
Normalized name: Albuterol Sulfate
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol sulfate HFA (ProAir® 90 mcg Inhalation Aerosol) rescue puffs as needed
Study: NCT04323280
Drug: Dexamethasone therapy
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 20MG once daily for 4 days with additional colchicine therapy for 3 months
Study: NCT00070265
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03018535
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab,1 g IV, day 1 and day 15
Study: NCT03018535
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone 1 g IV daily for 3 doses, then oral methylprednisolone (0.4 mg/kg/day) or oral prednisone (0.5mg/kg/day) for 27 days during Month 1, 3, 5.
Study: NCT05175131
Drug: Mebeverine+Simethicone
Normalized name: mebeverine
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: fixed-dose combination, film-coated tablets, 135 mg + 80 mg
Study: NCT05175131
Drug: Mebeverine
Normalized name: Mebeverine
DrugBank: Mebeverine (DB12554)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duspatalin®, coated tablets 135 mg
Study: NCT05175131
Drug: Simethicone
Normalized name: Simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Espumisan® capsules 40 mg
Study: NCT02638467
Drug: Bosutinib
Normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will receive 400mg of bosutinib once daily from day +30 after transplant, by mouth with food, preferably in the morning. Bosutinib will also be administered from day at least -45 to day -15 to assess the sensitivity of patient CML to this TKI.
Study: NCT02638467
Drug: Bone Marrow cells
Normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01140867
Drug: zonisamide
Normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: zonisamide 100 mg tablet
Study: NCT02261064
Drug: Telmisartan/Amlodipine low dose
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02261064
Drug: Telmisartan/Amlodipine high dose
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01823198
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01823198
Drug: Fludarabine Phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00912990
Drug: Cisatracurium
Normalized name: Cisatracurium
DrugBank: Cisatracurium (DB00565)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One intravenous dose: 0.2mg/kg/dose
Study: NCT00783835
Drug: Long-Acting Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-Acting Methylphenidate within the range of 18, 36, 54 and 76 milligram will be orally administered once daily up to Day 56.
Study: NCT03116906
Drug: BI 685509
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: to be given for a total of up to 15 days
Study: NCT01759108
Drug: Rebamipide
Normalized name: Rebamipide
DrugBank: Rebamipide (DB11656)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Patients will be randomized 1:1 to receive either 300mg/d (100mg x3/day) of rebamipide or placebo for 12 weeks together with their usual therapy.
Study: NCT02676947
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01904396
Drug: Carnitine
Normalized name: carnitine
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients who are found to be carnitine deficient will be started on carnitine replacement and their heart function will be monitored on carnitine.
Study: NCT04505644
Drug: lidocaine patch
Normalized name: LIDOCAINE 40 mg TOPICAL PATCH [Lidocaine Patch]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sham patch containing no study medication applied at 12 hours after cesarean delivery and removed 24 hours after delivery. A second sham patch containing no study medication applied at 36 hours after cesarean delivery and removed at 48 hours after delivery.
Study: NCT04505644
Drug: IV lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: received i.v. lidocaine infusion after induction of anesthesia, 2 mg/min if body weight \>70 kg or 1 mg/min if body weight \<70 kg.
Study: NCT04047706
Drug: IDO1 Inhibitor BMS-986205 25mg
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT04047706
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT04047706
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT04047706
Drug: IDO1 Inhibitor BMS-986205 50 mg
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT04047706
Drug: IDO1 Inhibitor BMS-986205 100 mg
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT02709512
Drug: ADI-PEG 20 plus Pem Platinum
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational Drug in combination approved standard of care treatment for this indication
Study: NCT03000556
Drug: 0.3% Sodium Hyaluronate Eye Drop
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients need to use 0.3% Sodium Hyaluronate Eye Drop for 3 month.
Study: NCT00324467
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose: 1.4 mg/m\^2 Administration: IV Push day 1 Schedule: Cycle 1, 2, 3, 4, 5\*, 6\* (Week 1, 4, 7, 10, 14, 17)~\* Cycles 5 and 6 of R-CHOP will be administered only to patients with a negative mid-treatment PET scan
Study: NCT00324467
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose: 45 mg/m\^2 Administration: IV infusion day 1 (or day 2) over 90 minutes-8 hours Schedule: Cycle 1, 2, 3, 4, 5\*, 6\* (Week 1, 4, 7, 10, 14, 17)~\* Cycles 5 and 6 of R-CHOP will be administered only to patients with a negative mid-treatment PET scan
Study: NCT00324467
Drug: Ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Premedication for R-CHOP Dose: 8 mg Route: PO Schedule: 15 min pre-CHOP chemotherapy
Study: NCT00324467
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Premedication for R-CHOP Dose: 12 mg Route: PO Schedule: 15 min pre-CHOP chemotherapy
Study: NCT00324467
Drug: Diphenhydramine
Normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Premedication for R-CHOP Dose: 50 mg Route: PO Schedule: Prior to rituximab and then q 4h during rituximab infusion
Study: NCT00324467
Drug: Ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 5000 mg/m\^2 (total dose per cycle) Administration: In 3 equally divided doses IV infusion days 1,2,3, over 2 hours Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
Study: NCT00324467
Drug: Mesna (IV)
Normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 5000 mg/m\^2 (total dose per cycle) Administration: In 3 equally divided doses IV infusion days 1,2,3 (with ifosfamide) over 2 hours Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
Study: NCT00324467
Drug: Mesna (oral)
Normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 2 g Administration: PO 2h and 4h after ifosfamide infusion on days 1,2,3 Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)